Shares of the drug maker – Bajaj Healthcare – rose as a lot as 11 per cent to hit file excessive of Rs 1,009.80 after it obtained license from Defence Research and Development Organisation (DRDO) to fabricate and market Covid remedy drug 2-Deoxy-D-Glucose (2-DG). Bajaj Healthcare is the second firm after Laurus Labs to obtain DRDO’s nod to market and manufacture 2DG.
2-Deoxy-D-Glucose” (2-DG) helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence. The drug works by selectively accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production, Bajaj Healthcare said in a press release.
“We are happy so as to add 2-Deoxy-D-Glucose to our rising product portfolios after receiving license from DRDO. The second waves of coronavirus is extra aggressive and greater in quantity than the primary. Our nations medical infrastructure is actually battling shortage of oxygen capacities. We hope the provision of an efficient remedy resembling 2-Deoxy-D-Glucose (2-GD) will significantly ease the strain and provide sufferers a lot wanted and well timed remedy choice. Most sufferers ailing from average to extreme signs can profit from using Deoxy-D-Glucose,” stated Anil Jain, joint managing director, Bajaj Healthcare.
The first batch of anti-COVID oral drug 2-DG, developed by the DRDO, was launched in May by Defence Minister Rajnath Singh and former Health Minister Harsh Vardhan.
As of 12:23 pm, Bajaj Healthcare shares traded 7.5 per cent greater at Rs 980, outperforming the Sensex which was down 0.5 per cent.
